Solara Active Pharma Sciences - PP

Solara Active Pharma Sciences - PP

425.20
+1.10
(0.26%)
hide
Key Fundamentals
Add Ratio
Market Cap
498.20 Cr
EPS
-
PE Ratio
-
Dividend Yield
0.00 %
Industry
-
52 Week High
524.90
52 Week Low
330.00
PB Ratio
3.24
Debt to Equity
-
Sector
-
Forecast For
Actual

Company News

View All News
Caret
positive
Solara Active Pharma Sciences received first call money of Rs. 4.88 crore for 3,71,779 partly paid-up rights equity shares. The company's Rights Issue Committee approved converting these shares from Rs. 3.50 paid-up to Rs. 7 paid-up per share. The first call amount was Rs. 131.25 per share on outstanding partly paid-up equity shares that were allotted on June 19, 2024. Following this conversion, the company's paid-up capital increased to Rs. 44.47 crore, comprising 3,61,54,267 fully paid-up equity shares, 1,17,61,546 partly paid-up rights shares with Rs. 7 paid-up, and 2,37,209 partly paid-up rights shares with Rs. 3.50 paid-up. The company will take steps for corporate actions and obtaining listing approvals for the converted shares.
neutral
Solara Active Pharma Sciences Reports No Deviation in Rights Issue Proceeds Utilization for Quarter Ended June 30, 2025Aug 13, 2025
Solara Active Pharma Sciences Limited submitted its monitoring agency report for the quarter ended June 30, 2025, confirming no deviation in the utilization of Rights Issue proceeds from stated objectives. The company raised Rs 449.95 crore through a Rights Issue conducted from May 28, 2024 to June 11, 2024. CRISIL Ratings Limited, the appointed monitoring agency, reported that Rs 292.75 crore has been utilized out of the total net proceeds of Rs 446.95 crore, with Rs 154.2 crore remaining unutilized. The funds were deployed for repayment of borrowings (Rs 233.61 crore utilized) and general corporate purposes (Rs 59.14 crore utilized). The company repaid loans to HDFC, RBL Bank, Yes Bank, and Radiant Computech Private Limited. Rs 10.97 crore remains in the monitoring agency account, with Rs 134.99 crore yet to be raised through a second call planned for FY 27.
positive
Solara Active Pharma Sciences delivered revenue of INR320 crores in Q1 FY26, marking 15% quarter-on-quarter growth. The company achieved gross margin of 54% and EBITDA of INR57 crores, reflecting 13% quarter-on-quarter growth. This represents the highest PAT in 12 quarters at INR105 million, resulting in EPS of INR2.5 per share. Developed markets contributed 77% of total sales. The company reduced debt by INR143 crores, bringing net debt-to-EBITDA ratio to 2.7x. Ibuprofen and derivatives contributed approximately 30% of business, down from previous 50% dependency. Management guided for 10% revenue growth and 15-20% EBITDA growth for FY26. The company operates at 60-65% capacity utilization and plans to carve out its CRAMS and polymer business into a separate entity with INR200 crores debt transfer.
View more

Automatic Screeners on ScanX

Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
20 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
20 Sept 2024 389.75 415.05

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication2 days ago
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 29, 2025
Closure of Trading WindowSep 26, 2025
Announcement Under Regulation 30 SEBI (LODR) - ClarificationSep 26, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Business Responsibility and Sustainability Reporting (BRSR)Sep 02, 2025
Reg. 34 (1) Annual Report.Sep 02, 2025
Notice Of The 8Th Annual General MeetingSep 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Intimation Regarding 100 Days Campaign - Saksham NiveshakAug 21, 2025
Receipt Of Call Money Pursuant To The First Reminder Notice Issued For Payment Of First Call Money On The Outstanding Partly Paid-Up Rights Equity Shares Of The Company.Aug 16, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 25, 2025
Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended June 30 2025.Jul 25, 2025
Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30 2025.Jul 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Dispatch Of First Reminder Notice For Payment Of First Call MoneyJul 02, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 01, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Appointment Of Internal Auditors Secretarial Auditor And Reappointment Of Cost Auditor.May 15, 2025
Appointment of Company Secretary and Compliance OfficerMay 15, 2025
Announcement under Regulation 30 (LODR)-RetirementMay 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 15, 2025
Statement Of Deviation And VariationMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
Audited Financial Results For The Quarter And Year Ended March 31 2025May 15, 2025
Announcement Under Regulation 30 - Press ReleaseMay 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 07, 2025
Announcement under Regulation 30 (LODR)-Change in Corporate Office AddressMay 05, 2025
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressMay 05, 2025
Incorporation Of Wholly Owned Subsidiary CompanyApr 29, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 09, 2025
Notice On The First Call Money Of The Rights Equity Shares.Apr 09, 2025
Announcement under Regulation 30 (LODR)-Meeting UpdatesApr 02, 2025
Closure of Trading WindowMar 26, 2025

Technical Indicators

RSI(14)
Neutral
40.97
ATR(14)
Less Volatile
19.89
STOCH(9,6)
Oversold
15.03
STOCH RSI(14)
Oversold
5.59
MACD(12,26)
Bearish
-3.97
ADX(14)
Weak Trend
11.50
UO(9)
Bearish
46.38
ROC(12)
Downtrend And Accelerating
-6.97
WillR(14)
Oversold
-97.28